Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Vaccines To Pay Off? Pivotal Candidates May Yield Two BLAs In 2006

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA appears likely to review both personalized and "off-the-shelf" cancer vaccine BLAs in 2006, potentially rewarding the oncology community’s durable faith in active immunotherapy.

You may also be interested in...



Therion for sale

Following the Phase III failure of its pancreatic cancer vaccine Panvac-VF, developer Therion is for sale. The company anticipates closing within several months, Therion said in a June 28 announcement. The firm no longer plans to file a BLA, which it had been targeting for filing by year-end (1Pharmaceutical Approvals Monthly May 2006, p. 11). A Phase III trial of Therion's prostate cancer vaccine Prostvac-VF remains on track to start later this year...

Dendreon To File Provenge BLA In 2006 Based On Survival Data

Dendreon plans to submit a BLA for its prostate cancer vaccine Provenge in 2006 following FDA feedback suggesting that existing data is sufficient for filing, the firm says.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel